Pharsight

1. Butoconazole Nitrate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5993856	PADAGIS US	Pharmaceutical preparations and methods for their administration	Nov, 2017 (6 years ago)

Drugs and Companies using BUTOCONAZOLE NITRATE ingredient

Market Authorisation Date: 07 February, 1997

Treatment: Method of treating a vaginal fungal infection in a female human

Dosage: CREAM;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.02	23 Dec, 2009	1	18 May, 2012	17 Nov, 2017	Eligible

Strength	Dosage	Availability
2%	CREAM;VAGINAL	Discontinued

BUTOCONAZOLE NITRATE family patents

2. Centany patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6013657	PADAGIS US	Pharmaceutical compositions containing mupirocin	Jul, 2018 (5 years ago)

Drugs and Companies using MUPIROCIN ingredient

Market Authorisation Date: 04 December, 2002

Treatment: NA

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
2%	OINTMENT;TOPICAL	Prescription

CENTANY family patents

3. Clindesse patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9789057	September, 2014	Decision	Thomas C. Riley et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5993856	PADAGIS US	Pharmaceutical preparations and methods for their administration	Nov, 2017 (6 years ago)
US6899890	PADAGIS US	Bioadhesive drug delivery system	Apr, 2023 (a year ago)
US9789057	PADAGIS US	Pharmaceutical delivery system	Dec, 2026 (2 years from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Method of treating bacterial vaginosis

Dosage: CREAM;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.02	05 Feb, 2015	1		27 Apr, 2023	Extinguished

Strength	Dosage	Availability
EQ 2% BASE	CREAM;VAGINAL	Prescription

CLINDESSE family patents

4. Entocort Ec patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5643602	PADAGIS US	Oral composition for the treatment of inflammatory bowel disease	Jul, 2014 (9 years ago)
US5643602 (Pediatric)	PADAGIS US	Oral composition for the treatment of inflammatory bowel disease	Jan, 2015 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Apr 29, 2019
M(M-178)	Apr 29, 2019

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 02 October, 2001

Treatment: Treatment of mild to moderate active chrohn's disease involving the ileum and/or the ascending colon and the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum a...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
3 mg	01 Feb, 2008	1	02 Apr, 2014	01 Jan, 2015	Extinguished

Strength	Dosage	Availability
3MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

ENTOCORT EC family patents

5. Evamist patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6299900	PADAGIS US	Dermal penetration enhancers and drug delivery systems involving same	Feb, 2017 (7 years ago)
US6923983	PADAGIS US	Transdermal delivery of hormones	Feb, 2017 (7 years ago)
US6818226	PADAGIS US	Dermal penetration enhancers and drug delivery systems involving same	Feb, 2017 (7 years ago)
US6978945	PADAGIS US	Dispensing device	Jul, 2022 (1 year, 8 months ago)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 27 July, 2007

Treatment: Female hormone replacement therapy for postmenopausal women

Dosage: SPRAY;TRANSDERMAL